Tonix Pharmaceuticals Announces Issuance of U.S. Patent for Crystalline Tianeptine Oxalate Salt, the Active Ingredient of TNX...
October 23 2019 - 7:00AM
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the
Company), a clinical-stage biopharmaceutical company, today
announced that the U.S. Patent and Trademark Office ("USPTO")
issued U.S. Patent No. 10,449,203 to the Company on October 22,
2019. This patent, “Tianeptine Oxalate Salts and Polymorphs,”
includes claims directed to crystalline tianeptine oxalate salts,
and disclosures directed to methods of using those crystalline
forms and their compositions. This patent, excluding possible
patent term extensions, is expected to provide Tonix with U.S.
market exclusivity until December 28, 2037.
Tonix’s novel oral formulation of one of the claimed tianeptine
oxalate salts, or TNX-601, is being developed as a potential
treatment for posttraumatic stress disorder (PTSD) and also as a
potential treatment for neurocognitive dysfunction associated with
corticosteroid use. Tianeptine modulates the glutamatergic system
indirectly and reverses the neuroplastic changes that are observed
during periods of stress and corticosteroid use. Tianeptine is a
weak mu-opioid receptor agonist, but does not have significant
affinity for other known neurotransmitter receptors. Currently
there is no tianeptine-containing product approved in the U.S.,
though tianeptine sodium (amorphous) has been available in Europe,
Asia, and Latin America for the treatment of depression since 1987.
TNX-601 is designed for daytime dosing and may provide improved
stability, consistency, and manufacturability as compared to the
amorphous sodium salt. TNX-601 is being developed under Section
505(b)(1) of the Federal Food, Drug and Cosmetic Act
(FDCA).
About Tonix Pharmaceuticals Holding Corp.
Tonix is a clinical-stage biopharmaceutical
company focused on discovering and developing small molecules and
biologics to treat psychiatric, pain and addiction conditions.
Tonix’s lead product candidate, TNX-102 SL*, is in development for
posttraumatic stress disorder (PTSD), fibromyalgia, agitation in
Alzheimer’s disease and alcohol use disorder (AUD). TNX-102
SL is in Phase 3 development as a bedtime treatment for PTSD (trade
name Tonmya**) and fibromyalgia, with topline data in PTSD expected
in the first half of 2020. The agitation in Alzheimer’s
disease program is Phase 2 ready and the development for AUD is in
the pre-Investigational New Drug (IND) application stage. Tonix is
advancing two other PTSD therapeutic programs in the pre-IND stage,
with different mechanisms than TNX-102 SL and designed for daytime
dosing: TNX-601 (tianeptine oxalate) and TNX-1600 (a triple
reuptake inhibitor). TNX-601 is in clinical formulation testing
outside of the U.S and is expected to be IND-ready in 2020.
Tonix has two programs for treating addiction
conditions: TNX-1300*** (double-mutant cocaine esterase) is in
Phase 2 development for the treatment of cocaine intoxication and
TNX-102 SL is in pre-IND development for AUD. Tonix’s preclinical
pipeline includes TNX-1500 (anti-CD154), a monoclonal antibody
being developed to prevent and treat organ transplant rejection and
autoimmune conditions, and TNX-1700 (rTFF2), a biologic being
developed to treat gastric and pancreatic cancers. Finally,
TNX-801 (live virus vaccine for percutaneous [scarification]
administration) to potentially prevent smallpox and TNX-701
(undisclosed small molecule) to prevent radiation effects are being
advanced as medical countermeasures to improve biodefense.
* TNX-102 SL (cyclobenzaprine HCl sublingual tablets) is an
investigational new drug and has not been approved for any
indication.
** Tonmya has been conditionally accepted by the U.S. Food and
Drug Administration (FDA) as the proposed trade name for TNX-102 SL
for the treatment of PTSD.
***TNX-1300 (T172R/G173Q double-mutant cocaine esterase 200 mg,
i.v. solution) is an investigational new biologic and has not been
approved for any indication.
This press release and further information about Tonix can be
found at www.tonixpharma.com.
Forward-Looking
Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of
forward-looking words such as “anticipate,” “believe,” “forecast,”
“estimate,” “expect,” and “intend,” among others. These
forward-looking statements are based on Tonix's current
expectations and actual results could differ materially. There are
a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements.
These factors include, but are not limited to, risks related to
failure to obtain FDA clearances or approvals and noncompliance
with FDA regulations; our need for additional financing;
uncertainties of patent protection and litigation; uncertainties of
government or third party payor reimbursement; limited research and
development efforts and dependence upon third parties; and
substantial competition. As with any pharmaceutical under
development, there are significant risks in the development,
regulatory approval and commercialization of new products. Tonix
does not undertake an obligation to update or revise any
forward-looking statement. Investors should read the risk factors
set forth in the Annual Report on Form 10-K for the year ended
December 31, 2018, as filed with the Securities and Exchange
Commission (the “SEC”) on March 18, 2019, and periodic reports on
Form 10-Q filed with the SEC on or after the date thereof. Tonix
does not undertake any obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
Contacts
Jessica Morris (corporate)Tonix
Pharmaceuticalsinvestor.relations@tonixpharma.com(212) 980-9159
Scott Stachowiak (media)Russo
Partnersscott.stachowiak@russopartnersllc.com (646) 942-5630
Peter Vozzo
(investors)Westwickepeter.vozzo@westwicke.com (443) 213-0505
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Apr 2023 to Apr 2024